Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Breast Cancer | Unmet Need | US/EU | 2017

Login to access report north_east
Contact sales account_box

The HER2-positive breast cancer treatment paradigm has undergone considerable change in recent years and is expected to evolve further as more novel therapies enter the market. The enthusiastic adoption of HER2-targeting biologics, Roche/Genentech’s Perjeta (pertuzumab) and Kadcyla (T-DM1), has increased the barrier of entry for new emerging therapies. However, unmet need still exists for the treatment of advanced/metastatic HER2-positive breast cancer. Our content examines the key drivers of prescribing and analyzes the areas of significant commercial opportunities.

Questions Answered:

  • What are the treatment drivers and goals for advanced/metastatic HER2-positive breast cancer?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for advanced/metastatic HER2-positive breast cancer?
  • What are the prevailing areas of unmet need and opportunity in advanced/metastatic HER2-positive breast cancer?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new, advanced/metastatic HER2-positive breast cancer drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in February 2017.

Key companies: Roche/Genentech, Novartis

Key drugs: Perjeta, Kadcyla, Tykerb/Tyverb

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east